These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 29601139)

  • 21. Extracellular volume fraction in dilated cardiomyopathy patients without obvious late gadolinium enhancement: comparison with healthy control subjects.
    Hong YJ; Park CH; Kim YJ; Hur J; Lee HJ; Hong SR; Suh YJ; Greiser A; Paek MY; Choi BW; Kim TH
    Int J Cardiovasc Imaging; 2015 Jun; 31 Suppl 1():115-22. PubMed ID: 25634119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Native T1 Mapping and Extracellular Volume Mapping for the Assessment of Diffuse Myocardial Fibrosis in Dilated Cardiomyopathy.
    Nakamori S; Dohi K; Ishida M; Goto Y; Imanaka-Yoshida K; Omori T; Goto I; Kumagai N; Fujimoto N; Ichikawa Y; Kitagawa K; Yamada N; Sakuma H; Ito M
    JACC Cardiovasc Imaging; 2018 Jan; 11(1):48-59. PubMed ID: 28624408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
    Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
    Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T1 mapping in children and young adults with hypertrophic cardiomyopathy.
    Parekh K; Markl M; Deng J; de Freitas RA; Rigsby CK
    Int J Cardiovasc Imaging; 2017 Jan; 33(1):109-117. PubMed ID: 27659477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Volumetric Assessment of Late Enhancement Provided by Cardiac Computed Tomography.
    Langer C; Schaefer P; Lutz M; Eden M; Hohnhorst M; Harders H; Faber L; Jansen O; Both M; Frey N
    J Comput Assist Tomogr; 2015; 39(5):797-803. PubMed ID: 26125299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
    Ho CY; Abbasi SA; Neilan TG; Shah RV; Chen Y; Heydari B; Cirino AL; Lakdawala NK; Orav EJ; González A; López B; Díez J; Jerosch-Herold M; Kwong RY
    Circ Cardiovasc Imaging; 2013 May; 6(3):415-22. PubMed ID: 23549607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Interstitial fibrosis is associated with left atrial remodeling and adverse clinical outcomes in selected low-risk patients with hypertrophic cardiomyopathy".
    Tondi L; Pica S; Crimi G; Disabato G; Figliozzi S; Camporeale A; Bernardini A; Tassetti L; Milani V; Piepoli MF; Lombardi M
    Int J Cardiol; 2024 Aug; 408():132135. PubMed ID: 38705206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left atrial fibrosis correlates with extent of left ventricular myocardial delayed enhancement and left ventricular strain in hypertrophic cardiomyopathy.
    Latif SR; Nguyen VQ; Peters DC; Soufer A; Henry ML; Grunseich K; Testani J; Hur DJ; Huber S; Mojibian H; Dicks D; Sinusas AJ; Meadows JL; Papoutsidakis N; Jacoby D; Baldassarre LA
    Int J Cardiovasc Imaging; 2019 Jul; 35(7):1309-1318. PubMed ID: 30790116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Texture signatures of native myocardial T
    Neisius U; El-Rewaidy H; Kucukseymen S; Tsao CW; Mancio J; Nakamori S; Manning WJ; Nezafat R
    J Magn Reson Imaging; 2020 Sep; 52(3):906-919. PubMed ID: 31971296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertrophic cardiomyopathy and left ventricular hypertrophy in hypertensive heart disease with mildly reduced or preserved ejection fraction: insight from altered mechanics and native T1 mapping.
    Wu LM; An DL; Yao QY; Ou YZ; Lu Q; Jiang M; Xu JR
    Clin Radiol; 2017 Oct; 72(10):835-843. PubMed ID: 28552325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.
    Małek ŁA; Werys K; Kłopotowski M; Śpiewak M; Miłosz-Wieczorek B; Mazurkiewicz Ł; Petryka-Mazurkiewicz J; Marczak M; Witkowski A
    Magn Reson Imaging; 2015 Jul; 33(6):718-24. PubMed ID: 25863138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of sarcomere and mitochondria-related mutations on myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Chung H; Kim Y; Park CH; Kim JY; Min PK; Yoon YW; Kim TH; Lee BK; Hong BK; Rim SJ; Kwon HM; Lee KA; Choi EY
    J Cardiovasc Magn Reson; 2021 Mar; 23(1):18. PubMed ID: 33658040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myocardial fibrosis imaging based on T1-mapping and extracellular volume fraction (ECV) measurement in muscular dystrophy patients: diagnostic value compared with conventional late gadolinium enhancement (LGE) imaging.
    Florian A; Ludwig A; Rösch S; Yildiz H; Sechtem U; Yilmaz A
    Eur Heart J Cardiovasc Imaging; 2014 Sep; 15(9):1004-12. PubMed ID: 24686257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of heart failure in hemodialysis-dependent end-stage renal disease patients with myocardial fibrosis quantification by extracellular volume on cardiac magnetic resonance imaging.
    Xu HY; Yang ZG; Zhang Y; Peng WL; Xia CC; Li ZL; He Y; Xu R; Rao L; Peng Y; Li YM; Gao HL; Guo YK
    BMC Cardiovasc Disord; 2020 Jan; 20(1):12. PubMed ID: 31924159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between the cardiac magnetic resonance derived extracellular volume fraction and feature tracking myocardial strain in patients with non-ischemic dilated cardiomyopathy.
    Azuma M; Kato S; Kodama S; Hayakawa K; Kagimoto M; Iguchi K; Fukuoka M; Fukui K; Iwasawa T; Utsunomiya D; Kimura K; Tamura K
    Magn Reson Imaging; 2020 Dec; 74():14-20. PubMed ID: 32898651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left ventricular function in patients with hypertrophic cardiomyopathy and its relation to myocardial fibrosis and exercise tolerance.
    Maragiannis D; Alvarez PA; Ghosn MG; Chin K; Hinojosa JJ; Buergler JM; Shah DJ; Nagueh SF
    Int J Cardiovasc Imaging; 2018 Jan; 34(1):121-129. PubMed ID: 28748418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue Characterization by Mapping and Strain Cardiac MRI to Evaluate Myocardial Inflammation in Fulminant Myocarditis.
    Li H; Zhu H; Yang Z; Tang D; Huang L; Xia L
    J Magn Reson Imaging; 2020 Sep; 52(3):930-938. PubMed ID: 32080960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy.
    Dass S; Suttie JJ; Piechnik SK; Ferreira VM; Holloway CJ; Banerjee R; Mahmod M; Cochlin L; Karamitsos TD; Robson MD; Watkins H; Neubauer S
    Circ Cardiovasc Imaging; 2012 Nov; 5(6):726-33. PubMed ID: 23071146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous assessment of late gadolinium enhancement grey zone in patients with non-ischaemic cardiomyopathy with T1ρ and native T1 mapping.
    Dong Z; Yin G; Yang K; Jiang K; Wu Z; Chen X; Song Y; Yu S; Wang J; Yang S; Ma X; Xu Y; Zhao K; Lu M; Xu X; Zhao S
    Eur Heart J Cardiovasc Imaging; 2023 Mar; 24(4):492-502. PubMed ID: 35793269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.